Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2131)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (129)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (855)
  3. JNCI: Journal of the National Cancer Institute (492)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (140)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pharmacokinetics (PK) and pharmacodynamics (PD) of a novel carcinoembryonic antigen (CEA) T-cell bispecific antibody (CEA-CD3 TCB) for the treatment of CEA-positive solid tumors
    Meeting Abstract

    Melero, I.; Segal, N. H.; Saro, J.; Ros, W.; Martinez-Garcia, M.; Argiles, G.; Moreno, V.; Ponce, S.; Marabelle, A.; Cleary, J. M.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Morris, M.; Vogelzang, N. J.; Sartor, O.; Armour, A.; Groaning, M.; Messmann, R.; Robarts, A.; Petrylak, D. P.; Tolcher, A.; Gordon, M. S.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Immune correlates for the efficacy of PEGylated Human IL-10 (AM0010) with nivolumab in renal cell cancer
    Meeting Abstract

    Naing, A.; Infante, J. R.; Wong, D. J.; Korn, M. W.; Aljumaily, R.; Papadopoulos, K.; Autio, K.; Pant, S.; Bauer, T. M.; Drakaki, A.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Post-progression outcomes from the phase 2 IMvigor210 study
    Meeting Abstract

    Necchi, A.; Joseph, R. W.; Loriot, Y.; Hoffman-Censits, J.; Perez Gracia, J. L.; Petrylak, D. P.; Zhu, Q.; Ding, B.; Kaiser, C.; Rosenberg, J. E.
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Outcomes of patients with metastatic urothelial carcinoma (mUC) with exclusive bone metastases: Focus on a special patient population
    Meeting Abstract

    Necchi, A.; Pond, G. R.; Pal, S. K.; Agarwal, N.; Bowles, D.; Plimack, E.; Yu, E. Y.; Ladoire, S.; Baniel, J.; Crabb, S.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Phase Ib study of PF-04136309 (an oral CCR2 inhibitor) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic adenocarcinoma
    Meeting Abstract

    Noel, M.; Lowery, M.; Ryan, D.; Wolpin, B.; Bullock, A.; Britten, C.; Jin, B.; Ganguly, B. J.; Taylor, C. T.; Yin, D.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) in patients (pts) with advanced (adv) chemotherapy-refractory (CT-Rx) esophagogastric (EG) cancer according to microsatellite instability (MSI) status: CheckMate 032
    Meeting Abstract

    Ott, P. A.; Le, D. T.; Kim, J. W.; Ascierto, P. A.; Sharma, P.; Bono, P.; Peltola, K.; Jäger, D.; Evans, T. R. J.; de Braud, F.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • BEACON CRC: Safety lead-in (SLI) for the combination of binimetinib (BINI), encorafenib (ENCO), and cetuximab (CTX) in patients (pts) with BRAF-V600E metastatic colorectal cancer (mCRC)
    Meeting Abstract

    Huijberts, S.; Schellens, J. H. M.; Elez, E.; Cuyle, P. J.; Van Cutsem, E.; Yaeger, R.; Fakih, M.; Montagut, C.; Peeters, M.; Desai, J.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; Defusco, P.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S. B.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Adjuvant anti-HER2 therapy, treatment-induced amenorrhea (TIA) and survival in premenopausal patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the ALTTO trial (BIG 2-06)
    Meeting Abstract

    Lambertini, M.; Campbell, C.; Bines, J.; Korde, L.; Izquierdo Delso, M. A.; Fumagalli, D.; Pritchard, K.; Wolff, A.; Jackisch, C.; Lang, I.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save